Clinical Trial Update: Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ribociclib in combination with an aromatase inhibitor versus physician’s choice of chemotherapy sequential endocrine therapy f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Kisqali (ribociclib) (ribociclib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Advanced Breast Cancer | Phase 2 | Status: RECRUITING